Gilead Sciences announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial
Gilead Sciences announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial indicating that the company’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrated 100% efficacy for the investigational use of HIV prevention in cisgender women.…